ELI LILLY & CO shares rose 4% premarket on June 8 following positive trial data for its next-generation obesity drug, retatrutide. The data suggests the drug could extend the lead of ELI LILLY & CO in the $200B obesity market by matching current top-tier efficacy at lower doses. For investors, these findings reinforce the company's competitive position as drugmakers increasingly compete on patient tolerability and dosing simplicity.
Eli Lilly shares rise on positive retatrutide data
Eli Lilly shares gained 4% after the company presented trial data for its next-generation weight-loss drug retatrutide at the American Diabetes Association meeting. Analysts noted that the 4mg dose produced weight loss comparable to current high-dose therapies while maintaining manageable tolerability levels.
Xurve View
洞察:
Xurve View











